Philip Morris International is a leading global organization in the tobacco industry, primarily known for manufacturing and distributing a variety of smokeable products, including cigarettes and heated tobacco devices. The company is committed to transforming its business by investing in reduced-risk products, promoting alternatives to traditional smoking, such as e-cigarettes and heated tobacco products that aim to deliver nicotine without the harmful effects associated with combustion. With a strong emphasis on innovation and sustainability, Philip Morris International is actively shifting its focus towards a smoke-free future, striving to create a healthier environment while still engaging its customer base. Read More
Big tobacco companies have made small investments in the cannabis space. Industry experts share with Benzinga what could be next for partnerships and investments.
NRG Energy Inc leads S&P 500's 2024 leaderboard with 70% YTD gain. Palantir follows with 64% surge, only stock from Cathie Wood's ARK funds in top performers.
While the market has rallied off its April lows, uncertainty continues to dominate investor sentiment. To avoid the volatility, consider these three stocks.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Philip Morris (NYSE:PM) and the best and worst performers in the beverages, alcohol, and tobacco industry.
In a sliding market, Philip Morris has defied the odds, trading up to $173.20 per share. Its 33.2% gain since November 2024 has outpaced the S&P 500’s 2.1% drop. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Philip Morris is expanding its medical cannabis strategy via Aurora and Avicanna. What it means for the future of Big Tobacco in the cannabinoid space.
Consumer staples are considered safe havens in turbulent markets due to their inelastic demand profiles. Surprisingly, the sector hasn’t played its shielding role over the past six months as it tumbled 13.7%. This drop was worse than the S&P 500’s 5.5% loss.
